Donald Orloski
Received a B.S. in Biomolecular Engineering from the PENN and an MS in Pharmacy/Drug Regulatory Affairs from Long Island University plus an MBA from Stevens. With over 30 years of expertise in Pharma with extensive regulatory, CMC and drug development experience, works as regulatory affairs consultant with G&L Scientific & adjunct professor at Long Island University.
EditorialThe need for robust quality management
It is a simple fact that the establishment of a robust quality management system (QMS) can both drive – as well as facilitate – regulatory compliance across all layers of business and operations in the pharma and MedTech industries. However, there is no doubt that the mention of QMS can ...